We have a robust and sustainable pipeline with 3 clinical stage assets (EMB-01, EMB-06 and EMB-07) and more than 10 preclinical stage candidates. Our proprietary FIT-Ig® platform and other technical capabilities enable us to target three strategic oncology areas (tumor targeting, dual checkpoint regulators, immune cell engagers) and maintain our strong momentum to advance additional preclinical assets to the clinic.
Program
Target
Indication
Line(s) of treatment
Mono/
Combo
Combo
PCC
IND-
Enabling
Enabling
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ
Key Regulatory Authorities
Current Status/Upcoming Milestone
Rights
Partners
Oncology
Clinical
EMB-01 EGFR/cMET
Advanced/metastatic GI Cancers(CRC, HCC, gastric, biliary tract cancer)
≥3L
Mono
FDA,NMPA
Completed patient’s enrollment in March 2025/Expected Phase Ib/II trial completion in Q4 2025
Global
/
mCRC
≥3L
Mono
NMPA
IND approval from the NMPA in May 2025/Expected Phase II initiation around year end of 2025
Global
/
mCRC
2L,3L
+Chemo
NMPA
IND approval from the NMPA in January 2024/Expected Phase I initiation pending interim data readout of Phase II mono
Global
/
EMB-07 ROR1/CD3
Solid tumors /relapsed or refractory lymphoma
≥3L
Mono
NMPA
Dose-escalation still ongoing/Expected Phase I trial completion in Q1 2026
Global
/
DLBCL
1L,2L
Combo
NMPA
IND approval in September 2025/Expected study initiation in Q2 2026
Global
/
Pre-Clinical
EM1032
ALPP(G)/ CD3
Solid tumors
/
TBD
/
Expected IND submission in Q1 2026
Global
/
EM1034
LY6G6D/ CD3
Solid tumors
/
TBD
/
Expected IND submission in Q4 2026
Global
/
Immunology
Clinical
EMB-06 BCMA/CD3
SLE、gMG
Relapsed/ Refractory
Mono
NMPA
Ongoing Phase I trials in SLE and gMG sponsored by Candid
China
Candid
TED
/
Mono
NMPA
Ongoing Phase I trial in TED sponsored by Candid
China
Candid
Pre-Clinical
EM1039
Undisclosed trispecific TCE
Autoimmune diseases (B cell related)
/
TBD
/
Expected initiation of IND-enabling studies by Q2 2026
Global
/
EM1042
Undisclosed TCE
Autoimmune diseases (Inflammatory cell related)
/
TBD
/
Expected initiation of IND-enabling studies by Q2 2026
Global
/
TCE Programs
Non-TCE Programs
Core Product
Key Product
TCE Programs
Non-TCE Programs
Core Product
Key Product
